A Phase 4 interventional study of Tibolone and Estradiol & medroxyprogesterone acetate in Menopausal Syndromes, sponsored by Far Eastern Memorial Hospital. Completed at 1 site in Taiwan. Open to female participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-02-23.
Sponsored by Far Eastern Memorial Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Menopausal syndromes includes somatic symptom, psychosomatic symptoms, sexual dysfunction and even urinary symptoms. Hormone therapy (HT) is widely used for controlling menopausal symptoms. Common HT for menopausal syndrome with intact uterus includes tibolone, estradiol valerate (E2V) 1mg \& medroxyprogesterone acetate (MPA) 2.5 mg, and conjugated equine estrogens \& MPA.
However, only a few literatures mentioned about the therapeutic effect of tibolone, but lack of comparison research about their therapeutic effect on somatic symptoms, psychosomatic symptoms, sexual dysfunction and even urinary symptoms. The knowledge of the above therapeutic effects should be important for choosing a suitable medication. Therefore, the aim of this study is to assess the therapeutic effect on somatic symptoms, psychosomatic symptoms, sexual dysfunction and even urinary symptoms between tibolone and E2V/MPA.
Far Eastern Memorial Hospital is the lead sponsor of 260 studies on the registry; 40 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Tibolone (2.5 mg per day)for 12 consecutive weeks. Tibolone should be paid by patient herself, and does not cover by Taiwan Government health insurance.
Drug: Tibolone
Estradiol valerate (E2V) 1mg \& medroxyprogesterone acetate (MPA) 2.5 mg per day for 12 consecutive weeks, and this drug is paid by Taiwan Government health care insurance.
Drug: Estradiol & medroxyprogesterone acetate
Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)
Drug pages: Estradiol · Medroxyprogesterone Acetate
Estradiol \& medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
Menopausal symptoms
To clarify any difference of reduction in menopausal symptom scores between these two groups
Time frame: 12 weeks
sexual function
To clarify any difference of improvements of sexual function scores between these two groups
Time frame: 12 weeks
lower urinary tract symptoms
To clarify any difference of improvements of lower urinary tract symptoms scores between these two groups
Time frame: 12 weeks
psychosomatic symptoms
To clarify any difference of improvements of psychosomatic symptoms scores between these two groups
Time frame: 12 weeks
Ran from Nov 2012 to primary completion in Jul 2021, 103 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tibolone
Far Eastern Memorial Hospital →